Pharmacogenomics: Bench to bedside

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 739-748

  Weinshilboum, Richard ^a   Wang, Liewei ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; 6 MERCAPTOPURINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ALLOENZYME; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; CAFFEINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEBRISOQUINE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HEAT SHOCK PROTEIN 70; HYDRALAZINE; IRINOTECAN; ISONIAZID; LIPOXYGENASE INHIBITOR; PROCAINAMIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ASTHMA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL PRACTICE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOXICITY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYLAMINE N-ACETYLTRANSFERASE; DNA; DRUG DESIGN; HUMANS; MARKETING; METHYLTRANSFERASES; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 4544253691     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1497     Document Type: Review

References (71)

1. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
2. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001)
3. Weinshilboum, R. M. The therapeutic revolution. Clin. Pharmacol. Ther. 42, 481-484 (1987).
4. Hardman, J. G., Limbird, L. E. & Gilman, A. G. The Pharmacological Basis of Therapeutics (McGraw-Hill Medical, New York, 2001).
5. Kalow, W. Pharmacogenetics: Heredity and the Response to Drugs (W. B. Saunders Co., Philadelphia and London, 1962).
6. Weber, W. W. Pharmacogenetics (Oxford Univ. Press, New York, 1997).
7. Price Evans, D. A. Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics (Cambridge Univ. Press, Cambridge, 1993).
8. Vesell, E. S. & Page, J. G. Genetic control of dicumarol levels in man. J. Clin. Invest. 47, 2657-2663 (1968).
9. Vesell, E. S. & Page, J. G. Genetic control of drug levels in man: antipyrine. Science 161, 72-73 (1968).
10. Wilkinson, G. R. in The Pharmacological Basis of Therapeutics (eds. Hardman, J. G., Limbird, L. E. & Gilman, A. G.) 3-29 (McGraw-Hill Medical, New York, 2001).
11. Price Evans, D. A. in Pharmacogenetics of Drug Metabolism. International Encyclopedia of Pharmacology and Therapeutics Vol. 34 (ed. Kalow, W.) 95-178 (Pergamon, New York, 1992).
12. Timbrell, J. A., Harland, S. J. & Facchini, V. Polymorphic acetylation of hydralazine. Clin. Pharmacol. Ther. 28, 350-355 (1980).
13. Reidenberg, M. M., Drayer, D. E., Levy, M. & Warner, H. Polymorphic acetylation of procainamide in man. Clin. Pharmacol. Ther. 17, 722-730 (1975).
14. Drayer, D. E. & Reidenberg, M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin. Pharmacol. Ther. 22, 251-258 (1977).
15. Price Evans, D. A., Manley, K. A. & McKusick, V. A. Genetic control of isoniazid metabolism in man. BMJ 2, 485-491 (1960).
16. Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980).
17. Weinshilboum, R. M., Otterness, D. M. & Szumlanski, C. L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52 (1999).
18. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. & Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586 (1977).
19. Kroemer, H. K. & Eichelbaum, M. 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56, 2285-2298 (1995).
20. Bertilsson, L. et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51, 388-397 (1992).
21. Gonzalez, F. J. et al. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus of chromosome 22. Genomics 2, 174-179 (1988).
22. Ingelman-Sundberg, M. & Evans, W. Unraveling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics 11, 553-554 (2001).
23. Johansson, I. et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
24. Aklillu, E. et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in the Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441-446 (1996).
25. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. 'Draft' Guidance for Industry: Pharmacogenomics Data Submissions. (November 2003).
26. Eichelbaum, M., Spannbrucker, N., Steincke, B. & Dengler, H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183-187 (1979).
27. Lennard, L., Van Loon, J. A. & Weinshilboum, R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989).
28. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
29. Schütz, E., Gummert, J., Mohr, F. & Oellerich, M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 341, 436 (1993).
30. Fenech, A. & Hall, I. P. Pharmacogenetics of asthma. Br J Clin Pharmacol. 53, 3-15 (2002).
31. Drazen, J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999).
32. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
33. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
34. Roses, A. D. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541-549 (2002).
35. Goldstein, D. B., Tate, S. K. & Sisodiya S. M. Pharmacogenetics goes genomic. Nature Rev. Genet. 4, 937-947 (2003).
36. Collins, F. S. Shattuck lecture - medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341, 28-37 (1999).
37. Nebert, D. W., Jorge-Nebert, L. & Vesell, E. S. Pharmacogenomics and 'individualized drug therapy': high expectations and disappointing achievements. Am. J. Pharmacogenomics 3, 361-370 (2003).
38. Consortium, T. I. H. The International HapMap Project. Nature 426, 789-796 (2003).
39. Bader, J. The relative power of SNPs and haplotypes as genetic markers for association tests. Pharmacogenomics 2, 11-24 (2001).
40. Zerhouni, E. The NIH Roadmap. Science 302, 63-72 (2003).
41. Klein, T. E. & Altman, R. B. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Pharmacogenomics J. 4, 1 (2004).
42. Service, R. F. Surviving the blockbuster syndrome. Science 303, 1796-1799 (2004).
43. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
44. Eisenhauer, E. A. From the molecule to the clinic - inhibiting HER2 to treat breast cancer. N. Engl. J. Med. 344, 841-842 (2001).
45. Salerno, R. A. & Lesko, L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5, 503-505 (2004).
46. Leighton, J. K. et al. Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 5, 507-511 (2004).
47. Ruano, G. et al. Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics 5, 513-517 (2004).
48. Trepicchio, W. L. et al. Pharmacogenomic data submissions to the FDA: clinical case studies. Pharmacogenomics 5, 519-524 (2004).
49. Bosma, P. J. et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
50. Bosma, P. J. Inherited disorders of bilirubin metabolism. J. Hepatol. 38, 107-117 (2003).
51. Monaghan, G., Ryan, M., Seddon, R., Hume, R. & Burchell, B. Genetic variation in bilirubin UPD-glucurono-syltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581 (1996).
52. Innocenti, F. & Ratain, M. J. 'Irinogenetics' and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Ther. 75, 495-500 (2004).
53. Guttmacher, A. E., Collins, F. S. & Drazen, J. M. Genomic Medicine (Johns Hopkins Univ. Press, Baltimore, 2004).
54. Terreri, A. & Spelsberg, T. C. Primer on Medical Genomics (Mayo Foundation for Medical Education, Rochester, 2004).
55. Guttmacher, A. E. & Collins, F. S. Welcome to the genomic era. N. Engl. J. Med. 349, 996-998 (2003).
56. Clayton, E. W. Ethical, legal, and social implications of genomic medicine. N. Engl. J. Med. 349, 562-569 (2003).
57. Remy, C. N. Metabolism of thiopyrimidines and thiopurines: S-methylation with S- adenosylmethionine transmethylase and catabolism in mammalian tissue. J. Biol. Chem. 238, 1078-1084 (1963).
58. Woodson, L. C. & Weinshilboum, R. M. Human kidney thiopurine methyltransferase: purification and biochemical properties. Biochem. Pharmacol. 32, 819-826 (1983).
59. Lennard, L. The clinical pharmacology of 6 mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329-339 (1992).
60. Szumlanski, C. et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15, 17-30 (1996).
61. Schaeffeler, E. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004).
62. Collie-Duguid, E. S. R. et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9, 37-42 (1998).
63. Wang, L., Sullivan, W., Toft, D. & Weinshilboum, R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 13, 555-564 (2003).
64. Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y. & Evans, W. E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94, 6444-6449 (1997).
65. Woodson, L. C., Dunnette, J. H. & Weinshilboum, R. M. Pharmacogenetics of human thiopurine methyltransferase: kidney erythrocyte correlation and immunotitration studies. J. Pharmacol. Exp. Ther. 222, 174-181 (1982).
66. Weinshilboum, R. & Wang, L. Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin. Pharmacol. Ther. 75, 253-258 (2004).
67. Mortimer, O. et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 47, 27-35 (1990).
68. Sindrup, S. H. & Broser, K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5, 335-346 (1995).
69. Perry Jr, H. M., Tan, E. M., Carmody, S. & Sakamoto, A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms to hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76, 1140125 (1970).
70. Woosley, R. L. et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear and the lupus syndrome. N. Engl. J. Med. 298, 1157-1159 (1978).
71. Cascorbi, I., Brockmoller, J., Mrozikiewicz, P. M., Muller, A. & Roots, I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev. 31, 489-502 (1999).